2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5 Mimọ ≥98.0% Olaparib Intermediate Factory
Iwa mimọ giga, iṣelọpọ Iṣowo
Olaparib ati Awọn agbedemeji ti o jọmọ:
Olaparib CAS 763113-22-0
2-Fluoro-5-Formylbenzonitrile CAS 218301-22-5
2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoic acid CAS 763114-26-7
1- (Cyclopropylcarbonyl) piperazine Hydrochloride CAS 1021298-67-8
3-Oxo-1,3-Dihydroisobenzofuran-1-Ylphosphonic Acid CAS 61260-15-9
| Orukọ Kemikali | 2-Fluoro-5-Formylbenzonitrile |
| Awọn itumọ ọrọ sisọ | 3-Cyano-4-Fluorobenzaldehyde |
| Nọmba CAS | 218301-22-5 |
| NỌMBA CAT | RF-PI451 |
| Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn Toonu |
| Fọọmu Molecular | C8H4FNO |
| Òṣuwọn Molikula | 149.12 |
| Ojuami Iyo | 80.0 si 84.0 ℃ (tan.) |
| Solubility | Tiotuka ni kẹmika |
| Brand | Ruifu Kemikali |
| Nkan | Awọn pato |
| Ifarahan | Yellow to Pa-funfun Lulú |
| Mimo | ≥98.0% |
| Ọrinrin (KF) | ≤0.50% |
| Lapapọ Awọn Aimọ | ≤2.0% |
| Igbeyewo Standard | Standard Enterprise |
| Lilo | Agbedemeji ti Olaparib (CAS: 763113-22-0) PARP-Inhibitor |
Package: Igo, apo apamọwọ Aluminiomu, Ilu paali, 25kg / Drum, tabi gẹgẹbi ibeere alabara.
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina ati ọrinrin.
2-Fluoro-5-Formylbenzonitrile (CAS: 218301-22-5) ni a lo ni igbaradi ti awọn agbo ogun heterocyclic bi awọn inhibitors PARP fun lilo iṣoogun.2-Fluoro-5-Formylbenzonitrile ni a lo bi agbedemeji ti Olaparib (CAS: 763113-22-0).Olaparib jẹ inhibitor moleku kekere ti PARP1/PARP2 (IC50: 5/1 nM) ṣugbọn ko ni imunadoko si PARP tankyrase-1 (IC50: 1.5 µM).Olaparib (AZD-2281, orukọ iṣowo Lynparza) jẹ itọju ailera ifọkansi ti FDA-fọwọsi fun akàn, ti o dagbasoke nipasẹ KuDOS Pharmaceuticals ati nigbamii nipasẹ AstraZeneca.O jẹ oludena PARP, idinamọ poly ADP ribose polymerase (PARP), enzymu kan ti o ni ipa ninu atunṣe DNA.O ṣe lodi si awọn aarun ninu awọn eniyan ti o ni awọn iyipada BRCA1 ajogun tabi BRCA2, eyiti o pẹlu diẹ ninu awọn ovarian, igbaya, ati awọn aarun pirositeti.Ni Oṣu Kejila ọdun 2014, olaparib ti fọwọsi fun lilo bi aṣoju ẹyọkan nipasẹ EMA ati FDA.Ifọwọsi FDA wa fun germline BRCA mutated (gBRCAm) to ti ni ilọsiwaju akàn ọjẹ ti o ti gba laini mẹta tabi diẹ sii ṣaaju kimoterapi.
